G1 Therapeutics (G1 Therapeutics) Debt-to-Equity : 1.58 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is G1 Therapeutics Debt-to-Equity?

G1 Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. G1 Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $55.90 Mil. G1 Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $35.39 Mil. G1 Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 1.58.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for G1 Therapeutics's Debt-to-Equity or its related term are showing as below:

GTHX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.58 Max: 1.58
Current: 1.58

During the past 9 years, the highest Debt-to-Equity Ratio of G1 Therapeutics was 1.58. The lowest was 0.04. And the median was 0.58.

GTHX's Debt-to-Equity is ranked worse than
92.81% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs GTHX: 1.58

G1 Therapeutics Debt-to-Equity Historical Data

The historical data trend for G1 Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G1 Therapeutics Debt-to-Equity Chart

G1 Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.16

0.58

1.22

1.58

G1 Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.22	1.84	0.97	1.30	1.58

Competitive Comparison of G1 Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, G1 Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G1 Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G1 Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where G1 Therapeutics's Debt-to-Equity falls into.

G1 Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

G1 Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	55.897)	/	35.386
	=	1.58

G1 Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	55.897)	/	35.386
	=	1.58

G1 Therapeutics (NAS:GTHX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

G1 Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

G1 Therapeutics (G1 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

G1H:Germany

Address

700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709

Website

https://www.g1therapeutics.com

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.

Executives

John V. Umstead	officer: Chief Financial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Rajesh Malik	officer: Chief Medical Officer	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Mark Avagliano	officer: Chief Business Officer	79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Terry L Murdock	officer: Chief Operating Officer
Bailey John E. (jack) Jr.	director, officer: President and CEO	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Andrew Perry	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark A. Velleca	director, officer: President and CEO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Monica R. Thomas	officer: General Counsel	700 PARK OFFICES, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Jennifer K. Moses	officer: CFO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
James S. Hanson	officer: General Counsel	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Norman Sharpless	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 22709
Jacks Lee	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Seth Rudnick	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS, MISSISSAUGA A6 L5N 0E4
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421
Soma Gupta	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709